Bharat Biotech inks pact with WU's School of Medicine for COVID-19 intranasal vaccine

According to a press release issued by the city-based vaccine maker, Bharat Biotech owns the rights to distribute the vaccine in all markets except the US, Japan and Europe. While the Phase I trials will take place in St Louis University's Vaccine and Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3mOj7gi
via IFTTT